|
On Tuesday, the U.S. Federal Circuit Court of Appeals denied Novartis’s attempt to prevent a generic manufacturer from marketing and selling its generic version of Novartis’s Entresto product. Although the appeal will continue, generic versions are now available pending the appeal.
Manage Inventory Ahead of Generic Launch
We encourage members to actively manage the inventory of the brand product and return any excess stock they do not anticipate needing. A high conversion rate to the generic is expected, although reimbursement metrics remain uncertain at this time.
This is now a multi-source generic launch, with Alembic positioned as a preferred PRxO supplier, offering more than 60% savings compared to the brand. Alembic product is expected to be auto-shipped, and price protection is anticipated to play a role in this transition.
Alembic Options
10294529-SACUBITRIL-VALSARTAN 97-103 MG TAB 180
10294545-SACUBITRIL-VALSARTAN 24-26 MG TAB 180
10294547-SACUBITRIL-VALSARTAN 49-51 MG TAB 180
10294528-SACUBITRIL-VALSARTAN 97-103 MG TAB 60
10294621-SACUBITRIL-VALSARTAN 49-51 MG TAB 60
10294622-SACUBITRIL-VALSARTAN 24-26 MG TAB 60
|